| Dr Joshua Sameer Pal, MD | |
|
10810 Connecticut Ave, Kaiser Permanente Kensington Medical Center, Kensington, MD 20895-2138 | |
| (301) 929-7100 | |
| Not Available |
| Full Name | Dr Joshua Sameer Pal |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 20 Years |
| Location | 10810 Connecticut Ave, Kensington, Maryland |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558520874 | NPI | - | NPPES |
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356444897 PECOS PAC ID: 3577476761 Enrollment ID: O20040109000444 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago
| Entity Name | Brenton D. Wynn, Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598953960 PECOS PAC ID: 1759321086 Enrollment ID: O20050505001146 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago
| Entity Name | Joshua Pal Md A Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699149898 PECOS PAC ID: 1355648759 Enrollment ID: O20160330001752 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago
| Entity Name | Dr Joshua Sameer Pal Md Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275997074 PECOS PAC ID: 6406140268 Enrollment ID: O20160802002764 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago
| Entity Name | Innovative Anesthesia Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154815264 PECOS PAC ID: 3678823176 Enrollment ID: O20180904002744 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua Sameer Pal, MD 2101 E Jefferson St, Kaiser Permanente Medicare Enrollment, Rockville, MD 20852-4908 Ph: (301) 816-2424 | Dr Joshua Sameer Pal, MD 10810 Connecticut Ave, Kaiser Permanente Kensington Medical Center, Kensington, MD 20895-2138 Ph: (301) 929-7100 |
News Archive
The United States Food and Drug Administration have issued a warning regarding some substances present in a brand of Ranitidine that could be carcinogenic. In their first warning issued on the 13th of this month, the FDA warns that one of the brands of Ranitidine, Zantac is said to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is a known carcinogen, the report reads based on lab data and is also found in the environment, food and water the report adds.
What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
Neurobiologists have known that a novel environment sparks exploration and learning, but very little is known about whether the brain really prefers novelty as such.
› Verified 3 days ago